To evaluate the efficacy and safety of tebentafusp-based regimens - tebentafusp monotherapy and in combination with anti-PD1 - compared to investigator's choice (including clinical trials with investigational agents, salvage therapy according to local standard of care (SoC)) in patients with advanced non-ocular melanoma.
Aim of the study
Chemotherapy is used as standard therapy for advanced melanoma. The aim is to stop tumor growth or shrink the tumor. In this study, we are investigating how the investigational drug tebentafusp works and whether tebentafusp alone or in combination with pembrolizumab helps patients with advanced melanoma to live longer.
Who can take part?
Participants with HLA A*02:01-positive melanoma
Procedure
Your participation in this study will last 2 years in the treatment phase and later 3 months in the follow-up phase. We will invite you to up to 104 appointments, but the number may vary. An appointment takes about 3 to 16 hours.
Compensation
Original study name
A phase II/III study of the drug tebentafusp as a single therapy and in combination with the drug pembrolizumab in participants with previously treated advanced melanoma with HLA-A*02:01 mutation.
BASEC number
2023-01269
Financial support from
Immunocore Limited